81069-02-5 Usage
Chemical Properties
12.0
Uses
Different sources of media describe the Uses of 81069-02-5 differently. You can refer to the following data:
1. sulfhydryl reactive cleavable heterobifunctional cross-linking reagent, pyridine-2-thione release can be monitored at 343 nm after reactions with sulfhydryl groups
2. It is a water-soluble, thiol cleavable, homobifunctional and amine-reactive crosslinking agent.
General Description
DTSSP is 3,3′-Dithiobis(sulfosuccinimidylpropionate), which contains an amine-reactive N-hydroxysulfosuccinimide (sulfo-NHS) ester at each end of an 8-carbon spacer arm. Sulfo-NHS esters react with primary amines at pH 7-9 to form stable amide bonds, along with release of the N-hydroxysulfosuccinimide leaving group. Proteins, including antibodies, generally have several primary amines in the side chain of lysine (K) residues and the N-terminus of each polypeptide that are available as targets for sulfo-NHS-ester crosslinking reagents. DSS, the non-sulfonated analog of DTSSP is also available for applications that require a membrane-permeable crosslinker.
Check Digit Verification of cas no
The CAS Registry Mumber 81069-02-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,1,0,6 and 9 respectively; the second part has 2 digits, 0 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 81069-02:
(7*8)+(6*1)+(5*0)+(4*6)+(3*9)+(2*0)+(1*2)=115
115 % 10 = 5
So 81069-02-5 is a valid CAS Registry Number.
81069-02-5Relevant articles and documents
DLL3-TARGETING MULTISPECIFIC ANTIGEN-BINDING MOLECULES AND USES THEREOF
-
, (2021/10/02)
The disclosure provides multispecific antigen-binding molecules that comprise a first antigen-binding moiety and a second antigen-binding moiety, each of which is capable of binding to CD3 and CD137, but does not bind to CD3 and CD137 at the same time; and a third antigen-binding moiety that is capable of binding to DLL3, preferably human DLL3, which induce T-cell dependent cytotoxity more efficiently whilst circumventing adverse toxicity concerns or side effects that other multispecific antigen-binding molecules may have. The present invention provides multispecific antigen-binding molecules and pharmaceutical compositions that can treat various cancers, especially those associated with DLL3, by comprising the antigen-binding molecule as an active ingredient.